Soligenix, Inc. (SNGX) surged 92.15 percent to $5.34, up $2.56 on Monday, after announcing that the FDA granted orphan drug designation to dusquetide, the active ingredient in SGX945, for the treatment of Behçet's Disease. The decision follows encouraging Phase 2a trial results showing biological efficacy and safety in patients. The stock opened at $3.79 and traded between $3.57 and $6.23, with volume spiking to 169.53 million shares, far above its average of 8.06 million on the Nasdaq. Soligenix's 52-week range is between $1.09 and $6.23.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.